Preclinical and clinical evaluation of epratuzumab (anti-CD22 IgG) in B-cell malignancies.

Article Details

Citation

Copy to clipboard

Leonard JP, Goldenberg DM

Preclinical and clinical evaluation of epratuzumab (anti-CD22 IgG) in B-cell malignancies.

Oncogene. 2007 May 28;26(25):3704-13.

PubMed ID

17530024 [ View in PubMed

]

Abstract

The vast majority of non-Hodgkin's lymphomas are of B-cell phenotype. Development of unlabeled or radiolabeled therapeutic monoclonal antibodies against the cell surface antigen, CD20, has revolutionized the treatment of these malignancies. It is clear that antibodies targeting other B-cell-specific molecules, such as CD22, also offer potential therapeutic benefit. Epratuzumab is a humanized anti-CD22 monoclonal, which has undergone preclinical and phase I/II clinical evaluation in patients with indolent or aggressive lymphoma. Data suggest that this agent is well tolerated, and can induce tumor regressions. Trials are currently evaluating its safety and activity in combination with rituximab (chimeric anti-CD20) and standard chemotherapy are ongoing. Initial results suggest that these regimens have acceptable toxicity, and that epratuzumab warrants further evaluation as an adjunct to standard lymphoma treatment regimens.

DrugBank Data that Cites this Article

Drug Targets

Drug	Target	Kind	Organism	Pharmacological Action	Actions
Epratuzumab	B-cell receptor CD22	Protein	Humans	Yes	Antibody Regulator	Details